Protective effects of Re-yan-ning mixture on Streptococcus pneumonia in rats based on network pharmacology
Autor: | Zhishu Tang, Kunxia Hu, Yunlan Wang, Zhisheng Wu, Xiao Song, Lizhu Han, Jing Kou |
---|---|
Rok vydání: | 2021 |
Předmět: |
Male
Drug animal structures media_common.quotation_subject Pharmaceutical Science Traditional Chinese medicine Pharmacology medicine.disease_cause 030226 pharmacology & pharmacy 01 natural sciences Signal pathway Rats Sprague-Dawley Food and drug administration 03 medical and health sciences 0302 clinical medicine Network pharmacology Drug Discovery medicine Animals pneumonia media_common Inflammation signal pathway Tumor Necrosis Factor-alpha Streptococcus business.industry lcsh:RM1-950 NF-kappa B General Medicine Pneumonia Pneumococcal medicine.disease Rats 0104 chemical sciences Disease Models Animal 010404 medicinal & biomolecular chemistry Pneumonia Streptococcus pneumoniae lcsh:Therapeutics. Pharmacology Complementary and alternative medicine traditional chinese medicine Molecular Medicine business Research Article Drugs Chinese Herbal Signal Transduction |
Zdroj: | Pharmaceutical Biology, Vol 59, Iss 1, Pp 209-221 (2021) Pharmaceutical Biology article-version (VoR) Version of Record |
ISSN: | 1744-5116 1388-0209 |
Popis: | Context Re-yan-ning mixture (RYNM) is a new national drug approved by China's State Food and Drug Administration for the treatment of colds, simple pneumonia and acute bronchitis. Objective To determine the mechanism of action of RYNM in the treatment of bacterial pneumonia. Materials and methods Using the network pharmacology approach, the multiple components, component candidate targets and multiple therapeutic targets of RYNM were screened and functionally enriched. Also, we established a rat Streptococcus pneumonia model to verify the results of network pharmacology enrichment analysis. Forty male SPF Sprague Dawley rats were divided into four groups of 10 rats: control (normal saline), model (normal saline), levofloxacin-intervened and RYNM-intervened groups. IL-10, NOS2, COX-1, IL-6, TNF-α and NF-κB in serum and BALF were detected by ELISA. Western blot detected IL-17, IL-6, TNF-α, COX-2 and Bcl-2. Results The network pharmacology approach successfully identified 48 bioactive components in RYNM, and 65 potential targets and 138 signal pathways involved in the treatment of Streptococcus pneumonia with RYNM. The in vivo experiments indicated that model group has visible inflammation and lesions while RYNM and levofloxacin groups have not. The RYNM exhibited its therapeutic effects on Streptococcus pneumonia mainly via the regulation of cell proliferation and survival through the IL-6/IL-10/IL-17, Bax/Bcl-2, COX-1/COX-2, NF-κB and TNF-α signalling pathways. Discussion and conclusions The present study demonstrated the protective effects of RYNM on Streptococcus pneumonia, providing a potential mechanism for the treatment of bacterial pneumonia with RYNM. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |